Drug Trial Radar · NCT06692452
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 24, 2024
Primary completion
Oct 1, 2027
Study completion Oct 1, 2032
Sponsor
- Lead sponsor
- Eric Jacobsen, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ipsen
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL). The name of the study drugs involved in this study are: * Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2)) * Standard of care CHOP therapy: * Cyclophosphamide (a type of alkylating agent) * Doxorubicin (a type of anthracycline antibiotic) * Vincristine (a type of vinca alkaloid) * Prednisone (a type of corticosteroid) * Standard of care BEAM conditioning regimen for autologous stem cell transplant: * Carmustine (a type of alkylating agent) * Etoposide (a type of Topoisomerase II inhibitor) * Cytarabine (a type of antineoplastic) * Melphalan (a type of alkylating agent)
Conditions
- Lymphoma
- Peripheral T Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Interventions
TazemetostatDrug
EZH2 inhibitor, 200 mg tablet, taken orally per protocol.
DoxorubicinDrug
Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.
VincristineDrug
Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.
PrednisoneDrug
Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.
CytoxanDrug
Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.
CarmustineDrug
Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.
EtoposideDrug
Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.
CytarabineDrug
Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care
MelphalanDrug
Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate (CRR)Time frame: Up to 18 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.